

Beslut vid Fru Berta Kamprads styrelsemöte 24 maj 2023

Johan Bengzon, FBKS-2023-29

Cellular reprogramming: a novel treatment for glioblastoma.

Anslag beviljat: 2024-2025

Carina Bernardo, FBKS 2023-19

Dissecting tumor heterogeneity, plasticity and drug response with organoid models.

Anslag beviljat: 2024-2025

Åke Borg, FBKS 2023-21

SCAN-B: to further expand and develop molecular biomarkers for the better of future breast cancer patients.

Anslag beviljat: 2024-2026

Thomas Breslin, FBKS 2023-43

MASS-X: Phase 0 clinical trial of Microbeam Radiotherapy in real patient phantoms.

Anslag beviljat: 2024-2025

Tommaso De Marchi, FBKS 2023-4

Proteogenomic analysis of ESR1 mutated breast cancers.

Anslag beviljat: 2024-2025

Sara EK, FBKS 2023-6

Primary ibrutinib resistance in mantle cell lymphoma, translational immuno-oncology investigations related to the practice changing TRIANGLE trial.

Anslag beviljat: 2024-2026

Cecilia Follin, FBKS, 2023-7

Intervention with Physical Activity for Childhood Cancer Survivors to prevent late complications and improve health (IPACCS).

Anslag beviljat: 2024

Roman Galeev, FBKS 2023-40

Susceptibility to therapy-related myeloid neoplasm after chemotherapy for solid tumors.

Anslag beviljat: 2024-2025

Ingrid Hedenfalk, FBKS 2023-36

Spatial and Temporal Aspects on the Origins and Evolution, Early Detection and Development of Treatment Resistance of Ovarian Cancer Subtypes and Their Ecosystems.

Anslag beviljat: 2024-2026

Mattias Höglund, FBKS 2023-3

Uroscan-seq: translation of molecular classification of urothelial carcinoma into clinical routines.

Anslag beviljat: 2024-2026

Tomas Jansson, FBKS 2023-27

Tailored nanoprobes for more specific target definition and boosted therapeutic efficacy in prostate brachytherapy.

Anslag beviljat: 2024-2026

Keivan Javanshiri, FBKS 2023-10

Validating a digital cognitive assessment tool in adolescents who experience cognitive impairment after receiving oncological treatment towards the central nervous system.

Anslag beviljat: 2024

Helena Jernström, FBKS 2023-25

Interplay between host and tumor factors in breast cancer.

Anslag beviljat: 2024-2026

Karin Jirström, FBKS 2023-14

Deciphering the temporal and spatial molecular heterogeneity of pancreatic and other periampullary cancer - from diagnosis to terminal disease. The CHAMP study.

Anslag beviljat: 2024-2026

Göran Jönsson, FBKS 2023-33

Improved knowledge on the significance of tertiary lymphoid structures in melanoma.

Anslag beviljat: 2024-2026

Niklas Loman, FBKS 2023-39

Nordic Trip - A translational randomized phase III study exploring the effect of the addition of Capecitabine to Carboplatin based preoperative chemotherapy in early triple negative breast cancer (TNBC).

Anslag beviljat: 2024-2025

Johan Malm, FBKS 2023-22

Complementing Clinical Decision making of Malignant Melanoma patients by Digital pathologyAI-imaging and ProteoGenomics. Impact of microenvironment and tumor heterogeneity on drug response.

Anslag beviljat: 2024-2026

Johan Malmström, 2023-24

Research infrastructure in single cell biology for cancer research.

Anslag beviljat: 2024-2026

Sofie Mohlin, FBKS 2023-20

Paraganglioma: HIF-2a as a new biomarker and treatment target.

Anslag beviljat: 2024-2026

Martin Nilsson, FBKS 2023-1

Individualized radiotherapy target contouring for anal cancer patients - Moving away from one size fits all.

Anslag beviljat: 2024-2025

Emma Niméus, FBKS 2023-11

Prognostic molecular signatures for radiotherapy resistance in locally recurring breast cancer for development of novel treatments.

Anslag beviljat: 2024-2026

Helena Nyström, FBKS 2023-23

PERELI- A phase 2, open label study of PEmigatinib and REtifanlimab in advanced dedifferentiated Liposarcoma.

Anslag beviljat: 2024

Gudrun Oskarsdottir, FBKS 2023-32

Early stage LUNG cancer and DYspnea - The ELUDY study.

Anslag beviljat: 2024-2025

Astrid Persson, FBKS 2023-35

Real-world data on ultra-hypofractionated radiotherapy in prostate cancer.

Anslag beviljat: 2024

Ann Rosendahl, FBKS 2023-41

Obesity and long-term breast cancer risks, prevention insights from transdisciplinary studies.

Anslag beviljat: 2024-2026

Lao Saal, FBKS 2023-18

Towards clinical implementation of multi-modal profiles and ctDNA monitoring in breast cancer.

Anslag beviljat: 2024-2026

Hanna Sartor, FBKS 2023-2

Enhancement of imaging strategies in breast cancer.

Anslag beviljat: 2024

Joanna Strand, FBSK 2023-9

Developing a theragnostic non-invasive platform for therapy and imaging of metastatic prostate cancer.

Anslag beviljat: 2024-2025

Agatheeswaran Subramaniam, FBSK 2023-13

Harnessing the ubiquitin-proteasome system for cancer therapy.

Anslag beviljat: 2024-2025

Vinay Swaminathan, FBKS 2023-31

Development of bench to bedside 3D breast cancer organoid models to investigate tumour-stromal interactions.

Anslag beviljat: 2024-2025

Filip Szczepankiewics, FBKS 2023-8

MRI-based biomarkers for outcome prediction and radiotherapy monitoring in prostate cancer.

Anslag beviljat: 2024-2025

David Ulmert, FBKS 2023-38

Evaluating a Novel Radioimmunotherapeutic Agent for Targeting TGF β -Driven Cancer-Associated Fibroblasts in Patients with Metastatic Pancreatic Adenocarcinoma.

Anslag beviljat: 2024-2026

Katarina Velickovic, FBKS 2023-37

Five-year recovery from breast cancer: Biopsychosocial promotive and risk factors to regaining health and quality of life.

Anslag beviljat: 2024

Oskar Vilhelmsson Timmermand, FBKS 2023-42

Non-invasive imaging of Glutathione Peroxidase mediated resistance to cancer therapies.

Anslag beviljat: 2024-2025

Anders Örbom, FBKS 2023-30

Optimization of PSA-targeted radionuclide therapy by addressing clinically relevant questions in animal models.

Anslag beviljat: 2024